GRK2 inhibits Flt-1+ macrophage infiltration and its proangiogenic properties in rheumatoid arthritis

Xuezhi Yang1, Yingjie Zhao2, Qi Wei1

  • 1Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei 230032, China.

PubMed

Insights

Targeting G-protein-coupled receptor kinase 2 (GRK2) reduces inflammation in rheumatoid arthritis (RA). Inhibiting GRK2 activity diminishes monocyte-derived macrophage infiltration and angiogenesis, offering a new strategy for RA treatment.

Area of Science:

  • Immunology
  • Molecular Biology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) involves monocyte-derived macrophage (MDM) infiltration, contributing to disease severity.
  • Previous studies showed G-protein-coupled receptor kinase 2 (GRK2) deletion reprograms macrophages to an anti-inflammatory phenotype.
  • The GRK2 interactome's role in RA pathogenesis remains understudied.

Purpose of the Study:

  • To investigate the role of GRK2 in the collagen-induced arthritis (CIA) mouse model.
  • To identify novel GRK2-interacting proteins and elucidate their mechanisms in RA.

Main Methods:

  • Genetic deletion of GRK2 in macrophages using GRK2f/fLyz2-Cre+/- mice.
  • RNA sequencing (RNA-seq) and dual-luciferase reporter assays.
  • Pharmacological inhibition of GRK2 activity in CIA mice.

Main Results:

  • GRK2 deletion in CIA mice improved synovial inflammation and M1 macrophage polarization.
  • Peroxisome proliferator-activated receptor gamma (PPARγ) was identified as a novel GRK2-interacting protein.
  • GRK2-PPARγ signaling inhibited fms-related tyrosine kinase 1 (Flt-1) expression, reducing macrophage migration and angiogenesis.
  • GRK2 inhibition diminished CIA pathology, inflammation, and angiogenesis.

Conclusions:

  • GRK2 plays a crucial role in promoting MDM infiltration and angiogenesis in RA via the GRK2-PPARγ-Flt-1 axis.
  • Targeting GRK2 activity is a promising therapeutic strategy for RA by inhibiting MDM infiltration and angiogenesis.